RSS Feeds
Search

Companies

Companies

Displaying 1..5 of 5 - per page
Order by
Decision Resources Inc.
The worldwide leader in market research publications, advisory services and consulting More
NorthShore University HealthSystem Research Institute
NorthShore University HealthSystem Research Institute More
Astex Therapeutics Limited
Astex uses a fragment-based approach to discover and develop small molecule molecularly targeted drugs for the treatment of cancer and other human diseases with significant unmet medical need. More
Fluofarma
High Content Screening Services More
BioVex
BioVex : Developing a new class of vaccines to treat and prevent cancer - OncoVEX and ImmunoVEX, and a functional genomics platform for gene determination in the nervous system - NeuroVEX More
Displaying 1..5 of 5 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Eli Lilly Drops Plans to Seek Approval For its Established Drug Alimta as a Treatment For Head And Neck Cancer
Nov 2010 - 5 pages - $500
Head and Neck Cancer - Pipeline Assessment and Market Forecast to 2017
Oct 2010 - 64 pages - $2,000
Methotrexate (Head and Neck Cancer) - Analysis and Forecasts to 2020
Oct 2011 - 43 pages - $2,000
Bleomycin (Head and Neck Cancer) –Analysis and Forecasts to 2020
Oct 2011 - 43 pages - $2,000
Nimotuzumab (Head and Neck Cancer) - Analysis and Forecasts to 2020
Oct 2011 - 42 pages - $2,000
Tykerb (Head and Neck Cancer) - Analysis and Forecasts to 2020
Oct 2011 - 40 pages - $2,000
Erbitux (Head and Neck Cancer) – Analysis and Forecasts to 2020
Oct 2011 - 40 pages - $2,000
Avastin (Head and Neck Cancer) –Analysis and Forecasts to 2020
Oct 2011 - 30 pages - $2,000
Head and Neck Cancer Therapy Area Pipeline Report
Nov 2010 - 417 pages - $1,495
Cisplatin (Head and Neck Cancer) –Analysis and Forecasts to 2020
Oct 2011 - 41 pages - $2,000
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us